← Back to headlines
Eli Lilly Reports Strong Q1 2026 Earnings Driven by Mounjaro and Zepbound
Pharmaceutical company Eli Lilly announced strong financial results for the first quarter of 2026, with significant growth attributed to the performance of its key drugs, Mounjaro and Zepbound.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
